



## **Retired Dow Corning chairman appointed to Starpharma Board**

**Melbourne, Australia: 17 November 2006:** Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) today announced the appointment of Mr Richard Hazleton, the former chairman of the US-based global corporation Dow Corning, as a Non-Executive Director.

Mr Hazleton began his Dow Corning career in 1965. He held numerous positions in engineering, manufacturing and finance, both in the US and Europe, before becoming Chief Executive Officer of the company in 1993, and Chairman of the Board of Directors and CEO in 1994. He retired from Dow Corning in 2001. Mr Hazleton also held the position of Chairman of Dendritic Nanotechnologies Inc (DNT) from 2004 and until Starpharma's acquisition of the company in October 2006.

"The appointment of Mr Hazleton is of major significance to Starpharma and will assist in our rapid expansion to the United States following our acquisition of DNT. His experience and contacts in international business will be a major asset to Starpharma and complement the skills and experience of our current Board," said CEO Dr Jackie Fairley.

The Chairman of Starpharma, Mr Peter Bartels added: "This is a major coup for Starpharma and we welcome wholeheartedly Dick to our Board. He joins at an ideal time for the company, when we are increasingly focused on expanding our profile and business in the United States to fully appreciate the value of our now expanded portfolio of dendrimer-based pharmaceutical and industrial products."

Mr Hazleton has served on the Boards of the American Chemistry Council and the Chemical Bank and Trust Company (Midland, MI, USA) as well as several non-profit social service agencies in Michigan and Belgium.

The appointment is effective from 1 December 2006.

---

### **About Starpharma:**

Starpharma Holdings Limited (ASX:SPL, USOTC:SPHRY) is a world leader in the development of dendrimer nanotechnology for pharmaceutical, life-science and other applications. SPL is principally composed of two operating companies, Starpharma Pty Ltd in Melbourne, Australia and Dendritic Nanotechnologies Inc in Michigan, USA. Products based on SPL's dendrimer technology are already on the market in the form of diagnostic elements and laboratory reagents.

The Company's lead pharmaceutical development product is VivaGel™ (SPL7013 Gel), a vaginal microbicide designed to prevent the transmission of STIs, including HIV and genital herpes.

In the pharmaceutical field Starpharma has additional specific programs in the areas of Drug Delivery and ADME Engineering™ (using dendrimers to control where and when drugs go when introduced to the body), Polyvalency (using the fact that dendrimers can activate multiple receptors simultaneously) and Targeted

Diagnostics (using dendrimers as a scaffold to which both location-signalling and targeting groups are added to allow location of specific cell type, such as cancer cells).

More broadly the company is actively exploring dendrimer opportunities in materials science with applications as diverse as adhesives, lubricants and water remediation.

SPL has a comprehensive IP portfolio that comprises more than 180 patents/applications issued and pending across 32 patent families - a unique level of IP concentration among nanotechnology companies.

**Dendrimers:** A type of precisely-defined, branched nanoparticle. Dendrimers have applications in the medical, electronics, chemicals and materials industries.

**Microbicides:** A microbicide inactivates, kills or destroys microbes such as viruses and bacteria. Microbicides may be formulated as gels, creams, sponges, suppositories or films with the purpose of reducing significantly the incidence of STIs. They are intended for vaginal or rectal use to afford protection for varying periods, from several hours up to days. Microbicides may also be designed to have a contraceptive function.

**Genital herpes:** A recurrent, lifelong viral infection caused by the sexually transmitted herpes simplex virus type-2 (HSV-2). It is one of the most prevalent STIs, estimated to infect between 15% and 25% of male and female adults in developed countries. This figure is expected to rise to about 39% for males and 49% for females by 2025, unless effective preventive measures are found to reverse the trend. Herpes is estimated to affect one in six adults in America and new cases cost more than US\$1.5 billion each year. The figures for Australia are similar with an estimated one in six adults suffering from genital herpes (3.4 million people).

HSV-2 infection has a marked effect on a sufferer's quality of life. The virus is highly contagious and women appear to be at greater risk of infection than men. HSV-2 infection can make people more susceptible to infection by HIV and increase the transmission rate of HIV. If transmitted from mother to baby, the disease has very serious consequences.

**American Depositary Receipts (ADRs):** Starpharma's ADRs trade under the code **SPHY** (CUSIP number 855563102). Each Starpharma ADR is equivalent to 10 ordinary shares of Starpharma as traded on the Australian Stock Exchange. The Bank of New York is the depositary bank.

**For further information:**

<b>Media</b>	<b>Starpharma</b> <a href="http://www.starpharma.com">www.starpharma.com</a>	
<b>Rebecca Piercy</b> <b>Buchan Consulting</b> Tel: +61 2 9237 2800 Mob: +61 422 916 422 rpiercy@bcg.com.au	<b>Dr Jackie Fairley</b>  Chief Executive Officer +61 3 8532 2704	<b>Ben Rogers</b>  Company Secretary +61 3 8532 2702 ben.rogers@starpharma.com